Genedata
{{Short description|Swiss bioinformatics company}}
{{Infobox company
| name = Genedata
| logo = Genedata Logo.png
| genre =
| foundation = {{Start date and age|1997}}
| founder =
| location_city =
| location_country =
| location = Basel, Switzerland
| key_people = Othmar Pfannes (Founder & CEO)
| area_served = Worldwide
| industry = {{unbulleted list|Bioinformatics|Biopharmaceutical|Life sciences}}
| products = https://www.genedata.com/products-services
| revenue =
| operating_income =
| net_income =
| num_employees = ~400
| parent =
| divisions =
| subsid =
| owner =
| homepage = https://www.genedata.com/
| dissolved =
| footnotes =
}}
[https://www.genedata.com/ Genedata] is a bioinformatics company that develops enterprise software solutions to accelerate biopharmaceutical research and development. Founded in 1997 by Othmar Pfannes, Genedata has since grown to approximately 400 employees. Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo positioning the company in the heart of biopharma clusters around the globe.
Today, top 25 biopharmaceutical enterprises, innovative biotechnology companies, and scientific research institutions use the [https://www.genedata.com/products-services Genedata Biopharma Platform] to increase the efficiency of their R&D operations. With its knowledgeable scientific experts, modular software portfolio, and collaborative approach, Genedata helps companies to more efficiently discover, develop, characterize, and manufacture innovative biotherapeutics of all modalities including antibodies, cell and gene therapies (CGTs), RNA, and vaccines.
Genedata's solutions drive digitalization, automation, standardization, and data FAIRness while complying with regulatory standards.{{Cite web |last=Fischer |first=Sascha |date=2023-04-18 |title=Accelerating time to market through digitalisation |url=https://www.ddw-online.com/accelerating-time-to-market-through-digitalisation-23192-202304/ |access-date= |website=Drug Discovery World (DDW) |language=en-US}}
In July 2024, Genedata joined the Danaher Group.
Genedata Products
Genedata developed its first product for drug target discovery in 1998.The Genedata Biopharma Platform encompasses purpose-built workflow and analysis systems that support discovery, development, and translational research, as well as technology-focused analytical workflows. These systems can be used either individually or together to connect distinct data streams within organizations.{{Cite web |title=The Genedata Biopharma Platform |url=https://www.genedata.com/products-services |access-date= |website=www.genedata.com}}
[https://www.genedata.com/products-services/screener Screener] – For assay data analytics and management in discovery and development {{Cite journal |last1=Fang |first1=Jie |last2=Singh |first2=Shivendra |last3=Cheng |first3=Changde |last4=Natarajan |first4=Sivaraman |last5=Sheppard |first5=Heather |last6=Abu-Zaid |first6=Ahmed |last7=Durbin |first7=Adam D. |last8=Lee |first8=Ha Won |last9=Wu |first9=Qiong |last10=Steele |first10=Jacob |last11=Connelly |first11=Jon P. |last12=Jin |first12=Hongjian |last13=Chen |first13=Wenan |last14=Fan |first14=Yiping |last15=Pruett-Miller |first15=Shondra M. |date=2023-07-06 |title=Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma |url=https://www.nature.com/articles/s41467-023-39717-6 |journal=Nature Communications |language=en |volume=14 |issue=1 |pages=4003 |doi=10.1038/s41467-023-39717-6 |pmid=37414763 |bibcode=2023NatCo..14.4003F |issn=2041-1723|pmc=10326052 }}
[https://www.genedata.com/products-services/expressionist Expressionist] – For MS-based characterization and QC of biotherapeutics {{Cite journal |last1=Dhenin |first1=Jonathan |last2=Lafont |first2=Valérie |last3=Dupré |first3=Mathieu |last4=Krick |first4=Alain |last5=Mauriac |first5=Christine |last6=Chamot-Rooke |first6=Julia |date=2023-07-21 |title=Monitoring mAb proteoforms in mouse plasma using an automated immunocapture combined with top-down and middle-down mass spectrometry |url=https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/pmic.202300069 |journal=Proteomics |volume=24 |issue=3–4 |pages=e2300069 |language=en |doi=10.1002/pmic.202300069 |pmid=37480175 |issn=1615-9853|doi-access=free }}
[https://www.genedata.com/products-services/selector Selector] – For NGS-based target discovery, bioprocess development, and QC of biotherapeutics{{Cite journal |last1=Schmieder |first1=Valerie |last2=Fieder |first2=Juergen |last3=Drerup |first3=Raphael |last4=Gutierrez |first4=Erik Arango |last5=Guelch |first5=Carina |last6=Stolzenberger |first6=Jessica |last7=Stumbaum |first7=Mihaela |last8=Mueller |first8=Volker Steffen |last9=Higel |first9=Fabian |last10=Bergbauer |first10=Martin |last11=Bornhoefft |first11=Kim |last12=Wittner |first12=Manuel |last13=Gronemeyer |first13=Petra |last14=Braig |first14=Christian |last15=Huber |first15=Michaela |date=2022-04-10 |title=Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool |url=https://www.sciencedirect.com/science/article/pii/S0168165622000591 |journal=Journal of Biotechnology |volume=349 |pages=53–64 |doi=10.1016/j.jbiotec.2022.03.010 |issn=0168-1656|doi-access=free }}
[https://www.genedata.com/products-services/biologics Biologics] – For covering the end-to-end biotherapeutics discovery workflow for all modalities{{Cite journal |last1=Furtmann |first1=Norbert |last2=Schneider |first2=Marion |last3=Spindler |first3=Nadja |last4=Steinmann |first4=Bjoern |last5=Li |first5=Ziyu |last6=Focken |first6=Ingo |last7=Meyer |first7=Joachim |last8=Dimova |first8=Dilyana |last9=Kroll |first9=Katja |last10=Leuschner |first10=Wulf Dirk |last11=Debeaumont |first11=Audrey |last12=Mathieu |first12=Magali |last13=Lange |first13=Christian |last14=Dittrich |first14=Werner |last15=Kruip |first15=Jochen |date=2021 |title=An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics |journal=mAbs |volume=13 |issue=1 |pages=1955433 |doi=10.1080/19420862.2021.1955433 |issn=1942-0870 |pmc=8366542 |pmid=34382900}}
[https://www.genedata.com/products-services/profiler Profiler] – For translational research and precision medicine development {{Cite journal |last1=Hartwig |first1=Christina |last2=Müller |first2=Jan |last3=Klett |first3=Hagen |last4=Kouhestani |first4=Dina |last5=Mittelstädt |first5=Anke |last6=Anthuber |first6=Anna |last7=David |first7=Paul |last8=Brunner |first8=Maximilian |last9=Jacobsen |first9=Anne |last10=Glanz |first10=Karolina |last11=Swierzy |first11=Izabela |last12=Roßdeutsch |first12=Lotta |last13=Klösch |first13=Bettina |last14=Grützmann |first14=Robert |last15=Wittenberger |first15=Timo |date=2024-02-02 |title=Discrimination of pancreato-biliary cancer and pancreatitis patients by non-invasive liquid biopsy |journal=Molecular Cancer |volume=23 |issue=1 |pages=28 |doi=10.1186/s12943-024-01943-x |doi-access=free |pmid=38308296 |pmc=10836044 |issn=1476-4598}}
[https://www.genedata.com/products-services/bioprocess Bioprocess] – For bioprocess development workflows {{Cite web |last=PhD |first=Vivienne Raper |date=2024-03-06 |title=Pharma Companies Embrace Unified Record Keeping |url=https://www.genengnews.com/topics/bioprocessing/pharma-companies-embrace-unified-record-keeping/ |access-date= |website=GEN - Genetic Engineering and Biotechnology News |language=en-US}}
[https://www.genedata.com/platform/chromatics Chromatics] – For streamlining chromatography data management and analysis{{Cite web |title=Bio-IT World Names Innovative Practices Winners |url=https://www.bio-itworld.com/news/2025/03/19/bio-it-world-names-innovative-practices-winners |access-date=2025-03-31 |website=Pubs - Bio-IT World |language=en}}
References
{{Reflist}}
{{Authority control}}
Category:Bioinformatics companies
Category:Research support companies